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Abstract
Benzodiazepines are widely prescribed hypnotic agents which have multiple proven neurological and respiratory side effects. 
However, literature is sparse with regards to the incidence and occurrence of new onset central sleep apnoea in individuals being 
treated with benzodiazepines for insomnia. We present a case report of a patient presenting with new onset central sleep apnoea 
secondary to long term usage of benzodiazepines, with resultant masking of his pre-existing obstructive sleep apnoea.
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Introduction
Benzodiazepines are the most widely prescri-
bed hypnotic agents for the short-term manage-
ment of insomnia [1]. These agents normally exert 
their influence by decreasing the sleep latency 
and prolongation of total sleep time [2], however, 
they worsen sleep quality by decreasing REM and 
N3 stages of sleep. Other possible side effects inc-
lude tolerance to the hypnotic effects [3], rebound 
insomnia upon abrupt discontinuation, reduced 
slow wave sleep [4, 5] and withdrawal effects. 
However, literature with regard to the incidence 
and occurrence of new onset central sleep apnoea 
(CSA) in individuals being treated with benzo-
diazepines for insomnia is limited to case reports 
with sparse texts on the pathophysiology behind 
it. We present a case of a patient with new onset 
central sleep apnoea secondary to long-term usage 
of benzodiazepines, with resultant masking of 
his pre-existing obstructive sleep apnoea (OSA).
Material and methods
A 53-year-old male, with no comorbid ill-
ness in the past, presented to the department of 
pulmonary, critical care and sleep medicine with 
complaints of snoring, excessive daytime somno-
lence, mild cognitive impairment and nocturia 
for a period of 1 year. He had a past history of 
usage of tablet alprazolam 0.5 mg at night time, 
which was prescribed by a medical practitioner 
for treatment of insomnia for the past six mon-
ths. The patient had an Epworth sleepiness score 
(ESS) of 15. His body mass index (BMI) was 22. 
The man was a non-smoker. On evaluation, his 
pulmonary function test and echocardiography 
were within normal limits. There was no history 
of any cardiovascular or cerebrovascular event. 
The man underwent a diagnostic polysomn-
graphy (PSG) Level 1 which recorded the presence 
of central apnoeic events (Figure 1, 2). He had an 
apnoea-hypopnoea index (AHI) of 20 with more 
than fifty percent of events being central, hence 
a  diagnosis of CSA was made in accordance 
with the American Academy of Sleep Medicine 
(AASM) guidelines [6]. 
The PSG was scored manually by a  sleep 
physician. In consultation with a psychiatrist, 
alprazolam was discontinued and the patient was 
initiated on non-benzodiazepine medication (zol-
pidem 5 mg once a day). The magnetic resonance 
imaging (MRI) of the brain was performed to eva-
luate CSA associated with neurologic disease; it 
was reported normal. On subsequent evaluation 
after 2 weeks, the patient reported a subjective mild 
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Sp02 — oxygen saturation ; wk — wake; reM — rapid eye movement sleep; resp events — respiratory events; S — supine; r — right lateral
Figure 1. Hypnogram showing numerous central sleep apnoeas and desaturations and poor quality sleep (most time spent in N2 with no 
reM sleep)
reOGA2 and LeOGA2 — right and left electrooculography; F3A2, C4A1, C3A2 and O2A1 — electroencephalograph; CeMG — Chin electromy-
ography; mSnore — snoring; T flow — thermistor flow; Can flow — nasal cannula flow; THO — thoracic muscle effort; ABD — abdominal muscle 
effort; effort sum — thorax and abdominal effort sum; Pulser — pulse rate; SPO2 — oxygen saturation; Body — body position 
Figure 2. Polysomnography five-minute window with epoch 421−430 showing central sleep apnoea in view of no effort with no flow
improvement in sleep quality with ESS getting bet-
ter to 11 from an initial value of 15 over a period 
of two weeks. The effect of alprazolam wears off in 
2 to 3 days as it has a half-life of around 11 hours. 
However, in view of persistent daytime som-
nolence, a repeated PSG was planned. Unexpecte-
dly, in the PSG, numerous obstructive hypopno-
eas were recorded with an AHI of 32 (Figure 3–5). 
There was a  complete absence of central ap-
noeas and hypopnoeas. The present study did 
not use the esophageal pressure measurements; 
differentiation between obstructive and central 
hypopnoea was performed manually. In general, 
central hypopnoeas are defined by a proportiona-
te decrease in both airflow and respiratory effort. 
Usually, there is no snoring, absence of chest-ab-
dominal paradox and the nasal pressure or PAP 
device flow signal is fairly rounded. 
Split night titration was done and a conti-
nuous positive airway pressure (CPAP) of 5 cm 
water was sufficient to abolish all the obstructive 
apnoea and hypopnoea events, however, few hy-
popnoeas persisted in supine REM sleep leading 
to a  „good titration” according to the AASM 
guidelines [6]. The sleep quality improved with 
supine REM achieved after continuous positive 
airway pressure (CPAP) titration (Figure 6, 7). The 
patient was continued on tablet zolpidem for one 
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Sp02 — saturation of oxygen; wk — wake; reM — reM sleep; S — supine; r — right lateral; IPAP — inspiratory positive airway pressure; 
ePAP — expiratory positive airway pressure
Figure 3. Hypnogram showing disappearance of central events and appearance of obstructive hypopneas in follow-up polysomnography which is 
titrated with CPAP (green arrow) achieving supine reM
reOGM2 and LeOGM2 — right and left electrooculographyl F3M2, C4M1, C3M2 and O2M1 — electroencephalograph; CeMG — Chin electromy-
ography; mSnore — snoring; T flow — thermistor flow; Can flow — nasal cannula flow; PatFlow — Patient flow using positive airway pressure 
device; THO — thoracic muscle effort; ABD — abdominal muscle effort; effort sum — thorax and abdominal effort sum; Pulser — pulse rate; 
SPO2 — oxygen saturation; Body — body position; IPAP — inspiratory positive airway pressure; ePAP — expiratory positive airway pressure
Figure 4. Polysomnography with ten epochs number 301−310 showing numerous obstructive hypopnoeas
more week and prescribed a continuous airway 
pressure of 6 cm water for nocturnal use. The man 
is currently on follow-up on CPAP only with no 
sedative, and reports an improved sleep quality 
and reduced daytime symptoms. The Epworth 
sleepiness score is now 5 with no limitation in 
social and workplace activity. 
Discussion
Usage of hypnotics for sleep induction and 
maintenance is the most common short-term ma-
nagement strategy for insomnia. However, benzo-
diazepines have been implicated in precipitating 
sleep apnoea, especially central sleep apnoea 
(CSA) in patients with heart failure and severe 
desaturations in patients with mild OSA [7]. 
This situation is complicated by many fac-
tors, misdiagnosis of OSA as insomnia, ease of 
access to certain sedatives and comorbid psy-
chiatric diseases. The other contributing factors 
are lack of awareness on the part of the physician 
to recognise the symptoms of choking, snoring, 
early morning headache suggestive of OSA and 
worsening of OSA by psychiatric medications. 
Moreover, if an airway obstruction occurs, aro-
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Figure 5. Polysomnography with ten epochs number 721−731 showing no residual hypopnoeas on positive airway pressure of 5 cm water
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Figure 6. No reM and minimal N3 stage activity recorded in initial 
polysomnography when patient was taking Alprazolam
wk — wake; reM — rapid eye movement sleep
Figure 7. Improvement in sleep quality with reM contributing to 14% 
of sleep after stopping alprazolam and on PAP titration
usals allow the patient to correct the apnoea. 
Benzodiazepines can prevent arousal by causing 
sedation, thereby worsening the obstruction 
and associated desaturation. However, another 
school of thought reasons that as OSA worsens 
in REM sleep, benzodiazepines by decreasing 
REM sleep and allowing for breathing pattern to 
stabilise, prevent OSA to manifest. Even though 
literature is sparse to support either hypothesis, 
a combination of the above mechanisms may nu-
llify each other as shown in a Cochrane database 
demonstrating no worsening of AHI by sedative 
drugs. Alprazolam was not directly evaluated, 
however, eszopiclone, zolpidem, flurazepam, te-
mazepam, nitrazepam, triazolam, sodium oxybate 
and Ramelteon were included in the studies of 
the database [8].
The occurrence of CSA has been reported 
by benzodiazepines because as central nervous 
system depressants, these drugs decrease the 
central respiratory drive which also has been 
challenged by authors claiming that hypnotics 
not only improve sleep but also decrease apnoea 
frequency probably by reducing arousals and 
elevating arterial pCO2 [9]. However, masking of 
OSA as CSA has not been reported in literature. 
Muscle relaxants like baclofen have been reported 
to cause CSA [10], thus giving a plausible reason 
to benzodiazepines to mask OSA as CSA by their 
weak myo-relaxant action.
Esophageal pressure measurement was not 
carried out for differentiating between central and 
obstructive events in our patient in view of lack 
of consent for the same. Hence, the differentiation 
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between obstructive and central hypopnoea was 
performed manually — rather visually. The AASM 
guidelines recommend esophageal pressure and 
respiratory inductance plethysmography (RIP) belts 
as gold standard for effort and RIP belts were used in 
our case. The AASM Task force members recognise 
that a decrease in RIP excursions cannot differentia-
te obstructive and central hypopnoeas because the 
excursions may decrease in both types of hypopno-
eas, Hence the use of snoring, inspiratory flattening 
and thoraco-abdominal paradox have been justified 
to diagnose obstructive hypopnoeas [6].
Non-benzodiazepine agents such as zopiclone 
and zolpidem may be preferable to use in the short-
term management of insomnia in OSA. Studies have 
documented that the use of zolpidem in doses up 
to 10 mg did not impede the application of CPAP 
in patients with severe OSA; however, there was 
a reduction in sleep latency and mean arousal index 
[10]. The short-term use has been advocated thro-
ugh various studies as a safe and effective strategy 
for improving compliance with CPAP in patients 
with comorbid psychiatric disorders [11−13].
Thus, it is prudent to evaluate a  patient 
prior to start of medical therapy for insomnia, 
especially in the patient subpopulation with 
a predisposition to obstructive sleep apnoea. 
Even though the exact mechanism need to be 
deciphered by larger studies, worsening of the 
underlying sleep apnoea or appearance of new 
central events can occur when indiscriminate or 
long-term prescription of benzodiazepine drugs 
is given to patients without complete evaluation. 
This can even mask the underlying obstructive 
sleep apnoea, thereby, delaying the diagnosis and 
preventing early institution of PAP therapy.
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